<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01305083</url>
  </required_header>
  <id_info>
    <org_study_id>AI2010-01</org_study_id>
    <nct_id>NCT01305083</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Udenafil Tablets in Erectile Dysfunction.</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Controlled, Multicentric Study to Assess the Efficacy and Safety of Udenafil Tablets in Patients Suffering From Erectile Dysfunction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abdi Ibrahim Ilac San. ve Tic A.S.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abdi Ibrahim Ilac San. ve Tic A.S.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, double blind, placebo controlled, multicentric, clinical study will assess
      the efficacy and safety of Udenafil (100 mg) tablets in patients suffering from erectile
      dysfunction(ED).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IIEF</measure>
    <time_frame>8 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the total score of IIEF at the end of the treatment compared to baseline.</measure>
    <time_frame>8 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in score of Question 3 (SEP2) and Question 4 (SEP3) of IIEF questionnaire at the end of the treatment period as compared to baseline.</measure>
    <time_frame>8 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall assessment of efficacy (GAQ) to the study medication at the end of the study.</measure>
    <time_frame>8 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Udenafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Ingredient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Udenafil</intervention_name>
    <description>Placebo-control</description>
    <arm_group_label>Udenafil</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Udenafil</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients of 18 to 60 years of age.

          -  Patients in a stable, monogamous sexual relationship with a female partner for at
             least 6 months and willing to maintain this relationship for the duration of the
             study.

          -  Patients with established diagnosis of erectile dysfunction (ED) of organic,
             psychogenic or mixed etiology for at least 6 months duration.

          -  Patient willing to attempt at least one sexual intercourse in a week for the entire
             treatment.

        Exclusion Criteria:

          -  Patients with total erectile failure or any other sexual disorder such as hypoactive
             sexual desire.

          -  Patients who have previously failed to respond to PDE-5 inhibitors like Sildenafil,
             Vardenafil or Tadalafil.

          -  Patients who have used other erectile dysfunction therapies within 14 days (2 weeks)
             prior to entering into this study (i.e. visit 1).

          -  Patients with hypogonadism or anatomical deformity of the penis such as severe penile
             fibrosis or Peyronie's disease or penile trauma.

          -  Patients with a history of major psychiatric disorder.

          -  Patients with a history of significant pathological cardiovascular conditions such as:
             congestive heart failure, life-threatening arrhythmia or ischemic heart disease within
             the past 6 months.

          -  Patients with a history of central nervous system disorders such as stroke, transient
             ischemic attacks or spinal cord injury or a radical prostatectomy or radical pelvic
             surgery.

          -  Patients with hypotension (&lt;90/50) or uncontrolled hypertension (&gt;170/100),
             uncontrolled diabetes, hepatic impairment (SGOT or SGPT levels &gt; 3 x Upper Normal
             Limit), renal impairment (serum creatinine &gt; 2.5mg/dl), hematological disorders such
             as bleeding disorders.

          -  Patients with a history of retinitis pigmentosa, proliferative diabetic retinopathy or
             non-arteritic anterior ischemic optic neuropathy (NAION).

          -  Patients with a history of sickle cell disease, multiple myeloma, leukemia or any
             other disorders that may cause priapism.

          -  Patients on concomitant treatment with nitrates/nitrites(NO) donor, CYP3A4 inhibitors,
             CYP3A4 inducers, anticoagulants, androgens, antiandrogens or trazodone.

          -  Patients with known hypersensitivity to PDE 5 inhibitors like Sildenafil, Vardenafil
             or Tadalafil.

          -  Patient with known diagnosis to AIDS or with a positive HIV result at study screening
             visit.

          -  Patients with any other serious concurrent illness or malignancy.

          -  Patients with continuing history of alcohol and / or drug abuse.

          -  Participation in another clinical trial in the past 30days.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mersin</city>
        <zip>33343</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2011</study_first_submitted>
  <study_first_submitted_qc>February 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2011</study_first_posted>
  <last_update_submitted>May 11, 2012</last_update_submitted>
  <last_update_submitted_qc>May 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Udenafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

